Moderate hyperhomocysteinemia and early-onset central retinal vein occlusion

Retina

Volumn 26, Issue 1, 2006, Pages 65-70

  Lattanzio, Rosangela ^a   Sampietro, Francesca ^a   Ramoni, Andrea ^a   Fattorini, Annalisa ^a   Brancato, Rosario ^a   D'Angelo, Armando ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Central retinal vein occlusion; Hypercoagulability; Hyperhomocysteinemia; Risk factors; Thrombophilia

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; METHIONINE; PYRIDOXAL 5 PHOSPHATE; HOMOCYSTEINE;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CENTRAL RETINA VEIN OCCLUSION; CONTROLLED STUDY; FEMALE; FOLIC ACID BLOOD LEVEL; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; MANTEL HAENSZEL TEST; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; SUPPLEMENTATION; VITAMIN BLOOD LEVEL; BLOOD; DIET RESTRICTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MIDDLE AGED; RETINA VEIN OCCLUSION;

ADULT; AGED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FASTING; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; MALE; METHIONINE; MIDDLE AGED; PYRIDOXAL PHOSPHATE; RETINAL VEIN OCCLUSION; RISK FACTORS; VITAMIN B 12;

EID: 33644856816     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006982-200601000-00011     Document Type: Article

References (34)

1. Cooney MJ, Fekrat S, Finkelstein D. Current concepts in the management of central retinal vein occlusion. Curr Opin Ophthalmol 1998;9:47-50.
2. The Eye Disease Case-Control Study Group. Risk factors for central retinal vein occlusion. Arch Ophthalmol 1996;114:545-554.
3. Vine AK, Samama MM. The role of abnormalities in the anticoagulant and fibrinolytic systems in retinal vascular occlusions. Surv Ophthalmol 1993;37:283-292.
4. Prisco D, Marcucci R, Bertini L, Gori AM. Cardiovascular and thrombophilic risk factors for central retinal vein occlusion. Eur J Intern Med 2002;13:163-169.
5. Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. Lancet 1999;354:407-413.
6. D'Angelo A, Selhub J. Homocysteine and thrombotic disease. Blood 1997;90:1-11.
7. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969;56:111-128.
8. Wenzler EM, Rademakers AJ, Boers GH, et al. Hyperhomocysteinemia in retinal artery and retinal vein occlusion. Am J Ophthalmol 1993;115:162-167.
9. Hansen L, Kristensen HL, Bek T, Ingerslev J. Markers of thrombophilia in retinal vein thrombosis. Acta Ophthalmol Scand 2000;78:523-526.
10. Pianka P, Almog Y, Man O, et al. Hyperhomocystinemia in patients with nonarteritic anterior ischemic optic neuropathy, central retinal artery occlusion, and central retinal vein occlusion. Ophthalmology 2000;107:1588-1592.
11. Larsson J, Hultberg B, Hillarp A. Hyperhomocysteinemia and the MTHFR C677T mutation in central retinal vein occlusion. Acta Ophthalmol Scand 2000;78:340-343.
12. Cahill M, Karabatzaki M, Meleady R, et al. Raised plasma homocysteine as a risk factor for retinal vascular occlusive disease. Br J Ophthalmol 2000;84:154-157.
13. Vine AK. Hyperhomocysteinemia: a risk factor for central retinal vein occlusion. Am J Ophthalmol 2000;129:640-644.
14. Boyd S, Owens D, Gin T, et al. Plasma homocysteine, methylene tetrahydrofolate reductase C677T and factor II G2021 OA polymorphisms, factor VIII, and VWF in central retinal vein occlusion. Br J Ophthalmol 2001;85:1313-1315.
15. Marcucci R, Bertini L, Giusti B, et al. Thrombophilic risk factors in patients with central retinal vein occlusion. Thromb Haemost 2001;86:772-776.
16. Brown BA, Marx JL, Ward TP, et al. Homocysteine: a risk factor for retinal venous occlusive disease. Ophthalmology 2002;109:287-290.
17. Lahey JM, Tunc M, Kearney J, et al. Laboratory evaluation of hypercoagulable states in patients with central retinal vein occlusion who are less than 56 years of age. Ophthalmology 2002;109:126-131.
18. Weger M, Stanger O, Deutschmann H, et al. Hyperhomocyst(e)inemia and MTHFR C677T genotypes in patients with central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2002;240:286-290. Epub 2002 Feb 21.
19. Adamczuk YP, Iglesias Varela ML, Martinuzzo ME, Cerrato GS, Forastiero RR. Central retinal vein occlusion and thrombophilia risk factors. Blood Coagul Fibrinolysis 2002;13:623-626.
20. Abu El-Asrar AM, Abdel Gader AG, Al-Amro SA, Al-Attas OS. Hyperhomocysteinemia and retinal vascular occlusive disease. Eur J Ophthalmol 2002;12:495-500.
21. Di Crecchio L, Parodi MB, Sanguinetti G, et al. Hyperhomocysteinemia and the methylenetetrahydrofolate reductase 677C-T mutation in patients under 50 years of age affected by central retinal vein occlusion. Ophthalmology 2004;111:940-945.
22. Hayreh SS, Zimmerman B, Podhajsky P. Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics. Am J Ophthalmol 1994;117:429-441.
23. Fermo I, Arcelloni C, Mazzola G, et al. High-performance liquid chromatographic method for measuring total plasma homocysteine levels. J Chromatogr B Biomed Sci Appl 1998;719:31-36.
24. Camp VM, Chipponi J, Faraj BA. Radioenzymatic assay for direct measurement of plasma pyridoxal-5′-phosphate. Clin Chem 1983;29:642-644.
25. Bandello F, Vigano D'Angelo S, Parlavecchia M, et al. Hypercoagulability and high lipoprotein(a) levels in patients with central retinal vein occlusion. Thromb Haemost 1994;72:39-43.
26. Larsson J, Olafsdottir E, Bauer B. Activated protein C resistance in young adults with central retinal vein occlusion. Br J Ophthalmol 1996;80:200-202.
27. D'Angelo A, Beltrametti C. Venous disease. In: Carmel R, Jacobsen DW, eds. Homocysteine in Health and Disease. Cambridge, UK: Cambridge University Press; 2001:401-414.
28. Cahill MT, Stinnett SS, Fekrat S. Meta-analysis of plasma homocysteine, serum folate, serum vitamin B12, and thermolabile MTHFR genotype as risk factors for retinal vascular occlusive disease. Am J Ophthalmol 2003;136:1136-1150.
29. Fermo I, Vigano' D'Angelo S, Paroni R, et al. Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial thrombosis. Ann Intern Med 1995;123:747-753.
30. D'Angelo A, Coppola A, Madonna P, et al. The role of vitamin B12 in fasting hyperhomocysteinemia and its interaction with the homozygous C677T mutation of the methylenetetrahydrofolate reductase (MTHFR) gene. A case-control study of patients with early-onset thrombotic events. Thromb Haemost 2000;83:563-570.
31. den Heijer M, Brouwer IA, Bos OM, et al. Vitamin supplementation reduces blood homocysteine levels: a controlled trial in patients with venous thrombosis and healthy volunteers. Arterioscler Thromb Vasc Biol 1998;18:356-361.
32. Van den Berg M, Boers OH, Franken DO, et al. Hyperhomocysteinaemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease. Eur J Clin Invest 1995;25:176-181.
33. Chambers JC, Ueland PM, Obeid OA, et al. Improved vascular endothelial function after oral B vitamins: an effect mediated through reduced concentrations of free plasma homocysteine. Circulation 2000;102:2479-2483.
34. Undas A, Domagala TB, Jankowski M, Szczeklik A. Treatment of hyperhomocysteinemia with folic acid and vitamins B12 and B6 attenuates thrombin generation. Thromb Res 1999;95:281-288.